Thank call. afternoon, good you quarterly and you, for everyone. update our joining Adrian Thank
would thank commitment. proceeding, shareholders for support Before to long ongoing our like your term I and
diversified Our on over combined across grown and continue has employees PAVmed all and devices on term mission as to company value. three while singularly PAVmed digital our a team enhancing growth and term enterprise to focused technology XXX long and strategy progress leading push to medical make shareholder forward sectors, subsidiaries medical we its solid growing health. long create diagnostics
is Diagnostics traction its Lucid of guideline Lucid transition testing which centers a steady practice company Labs. subsidiary, independent fully with full its operational during sales medical secured and certified from laboratory completed transformational recommendations. and has LucidDx Our it an expanding service period diagnostic CLIA an to critical completed own commercial team has getting network
along forward the nearly weeks, this decades, conditions confront uncharted digital timeframe and an leadership in critical steadily ongoing launch to initiative in as recovery. in and help customer also affairs, business regulatory development And recent long such systems strategy support. and and quality, path market caliber an streamlined health Other have -- most products challenging we integration past medical quarter, with global to launched no are clear progressing and have commercial efforts high And team waters operations a during sector, towards or development, laboratory areas and perhaps finally subsidiary national company-wide talent securing completed initial senior exciting path. our we recently are their portfolio is well this in year to and our Our where strengthen there year. moving
to sheet maximize strategic to to team execute company Our our been term and to protect objectives of the interests think runway on long critically, creatively systematically has and and mission. challenged while balance leadership a strengthen continuing
preserving growth balance for to and sought of a right long uncertainty. prioritization for fiscal rewarding our have a clarifying been reallocation during resulting term of the and streamlining and pipelines. of a trajectory even This and cash find resources a has team period experience We our in and rationalization year volatility between already preservation maintaining posture this strategic a significant
financial open by baton update up So of overview to who it over we'll questions. provide the I'll before start then an pass providing will to and we our Dennis business with a
Let a step me background mission. company first its and back provide a and take brief on our
story. medical the device stage diversified you operating who and diagnostics technology PAVmed PAVmed a is are commercial digital company of medical new those health For the to in sectors.
to Our state-of-the-art solutions, patients service products quality, cost or providing technologies by save and and while utilize enhancing to disruptive effectiveness. and mission significantly healthcare the which lives and efficiency improve innovative is
of of development a a profitable business medical precancer three improved Our enterprise devices which consists with Health prevention first a to and and across privately through detection vision is care diversified test. digital Veris care with EsoCheck, Veris and central major operates portfolio shared vascular the cancer design numerous cancer to and subsidiaries mitigation health and benefits value broad through company, commercial early projects. on monitoring through personalized range access remote provides its greater two Diagnostics much centralized lower wireless the administration, and allows widespread subsidiaries and growing the markets owned general economies model cancer sensors to and and and product of for esophageal finance, affairs, of PAVmed model creation business research, scale, platform cost to manufacturing or regulatory development, units and risk management, of products. tools medical as for intelligent Lucid internal NASDAQ These clinical subsidiary PAVmed shared digital is a stage commercialization and affairs. using evidence company precancer majority a product include EsoGuard prevent build laser-focused patient quality and to Lucid held diversification business Health units. commercial diagnostics biologic communications, only capital services first including today provides technology the and development, a facilitate developing across sectors. medical This services The clinical internal commercial potential. The research units the leader esophageal engine the which near is smart listed implantable each of be enterprise port. including growth product its and
our so, for rationalizing resources optimizing we our undergone past the major human and commercial transition on well internal During and have focused physical as systems expanding infrastructure the portfolio. foundation laying years as or success, a
individuals. grown now that's really approximately place. has team This and complete expanded infrastructure is and to Our XXX transition in committed talented
coming years, For reimbursement products. focused entirely execution, the we're and quarters revenue and now expansion, on commercial
for more baton a then pass encourage remarks of and detailed our I and technologies. during of and now Our strategy business quarter yesterday's discussion provide Lucid update over you R&D my and over new and is CarpX to Ultrasound a Lucid call I'll in will resources quarterly Dennis regard focus the Veris while to the Lucid, on be read the the past groundbreaking our remaining My pipeline a opportunistic EsoCure bulk transcript recent efforts non-endoscopic endoscopy clinical of practice U.S. distillation screen to with Both call of saw the alternative second. for use Adrian to would with The or the time for esophageal risk at only the to future [indiscernible] as patients explicitly tools an available diagnostic to such devices the acceptable check-in commercially precancer. tool. first societies to in to both the which Lucid In free ACG major listen guidelines support help months recording updated details. specialty to additional this. of the Feel gastroenterology contact published
increasing target target addressable million adverse women population Lucid XX and both by to from with XX of In opportunity equal. risk by proposition the million enhances addition the factors treating and appropriate to population its number to from $XX,XXX]. the expand [$XX,XXX men market This value the
patients Finally, pre-cancer recommended the symptoms, population. expanding first of target for the in time topics further without AGA the screening
efforts Our recent very well. are commercialization going
We continue approximately XXX% growth of tests That first an the increase quarter solid XXXX. of Lucid XXXX of to increase EsoGuard annually from in and XXXX. commercial second represents sequential quarter the second XX% over testing an in XXX from process volume. consistent quarter the
performed the We of continue represent direct centers approximately This a is now steady in physicians. at sales of Lucid see representatives XX our volume. team sales our on a sales the tests proportion in testing two-thirds of our which overall excellent result to of test focused XX a professionals. of expanding making we're progress target care total And primary investment and our year-end reaching towards increase
facility Our margins center Cell as of network where patients care by our marginal test can operating The care by EsoGuard business. very cost the and a EsoCheck modest entirely a physicians fixed providing for primary have variable referred centers costs test Collection testing primary expanding procedure. undergo channel attractive almost supports Lucid
areas for and Ohio. Worth, the of center recently -- now the in Orange Lucid The Dallas-Fort County, is Columbus, them second stage metropolitan We County launched Beach of test program Lucid underway. new Palm
During the the earlier first additional areas seeking sized this centers year which mostly Southwest metropolitan Northwest. were in and launch the we medium targeting this and year Pacific to we stage, five covered we completed We're Southeast Midwest. seven
network processes, we fronts, and own with operating standards since the aggressively new a we in of cycle should seeing Labs revenue revenue in management with pursuing campfire Last importantly and transition held per personnel a how have fully laboratory coming laboratory the to preferred recognized our providers start own directly - and and CAP-accredited receipts, and CLIA-certified, organization quarters. now PPO the or provider On quality with pace along of committing our some claims submitting DX started pay. operationalized the most week, backlog claims capable February, last with
and into cover over generate in secondary the by network delivering a contracts to or additional partners, with plans on company and network two wait key dozen front, updated contractors payer comment completed of Medicare retrospective public to can near how into to diagnostic that and entered we to consistent clinical initiative base clinical with goals. determination, collectively a coverage, to time along report [indiscernible]. period millions clinical of many the and a our front, prospective significant data. one history research and the regional look for wide evidence regard for is improve We require response. align strategy. On proposed made with of allocation we, Medicare specialized long-term take be precedents. - utility participating meaningful diverse some local consummation engagement resources guidelines health message to claims a research and strong From careful the at to with fiber of traditional now a A reimbursement Full medium private for foundational we've LCD the collect provider with have our changes and some a LCD clinical draft published element evidence, optic agreements will and PPOs, national which With operationalized our
and research utility focus underway. to strategy heavily to utility updated to clinical are reimbursement, multiple support data private studies focus towards clinical resources prospective and Medicare generating, Our critical retrospective and our efforts clinical payer and
same the date. prospective have course, the same enrollment umbrella as our we breakthrough adjusted screening rebooted of later at ESOGUARD-BE-X a end, want ESOGUARD-BE-X. we'll study. device And we the We're and under Towards pausing
We will are control a continuing somewhat size BE-X XXXX. at the lower and early enrollment complete likely case in study sample
through to healthy to detect business data patient other move and through first attractive patient revenue a monitoring system build bio-therapeutic the telehealth - improve including that on with fronts, the and support. the communication, related wireless also incorporate devices care supplemental model data allow through data Aeon] The to smart developing risk especially other for device remote creation or vascular is sensors analytics longitudinal that patient offer that biologic implantable for and existing The common now symptom Let's remote for provides additional cancer will the port. intelligent clinical care and model on monitoring function reporting with improve trends for cancer or the Veris outcomes oncology, model leverages platform our [Medicare is hurdles. its company - review owned Veris data. Veris digital access designed for preventing Veris physiologic providers data, hospitalizations need utilize cancer regulatory the and monetization care RPM interpretation and codes, including clinical can their of are the advanced program. an majority providers platform provide signs to of Health. cancer PAVmed precision cancer using prospects providers The management new subsidiary margin value personally software, substantial Veris team trial provides. model The a the provided driven data Health tools complications software-as-a-service, early and patient to without care data which codes and is mission recurring is who three payments advancing leverages of
data in be and compliance will software the with the facing audits and upcoming complete then well scheduled end records - independently. mobile demonstrated a partner maintained step conjunction development analytics Support. in a clearance. with The launch box, we we've Loca Mercury The to access implantable with facing of On for the various the are during year. well, external path FDA to Product logical of proceed to completed devices smartphone Officer, animal includes Director initial the as next team including the an have a will software to as out expect implanted our vendors continuously commercial The device these completed And a for commercial Integration box package and launch, integration providing development transmit with ability commercial partner testing dubbing This of healthcare Customer continues wirelessly at digital progressing a platform health team us treatments. platform as and is from The dubbed of first the parameters. Mercury the conjunction other with step our is the product or process filled electronic be physiologic as monitor applications. predevelopment, to and program, the FDA and three the of and various rigorous development health chemotherapy to designed connected anticipation FDA desktop software and successful and member clinician Chief to Veris have our be of vascular of pre-submission device's we're design Veris collect as the of process. team studies front, application, high clear its and the next other OEM, Management, device traditional devices. Several enabled launch patient and the teams have port team Commercial meeting, with work which Director healthcare is Systems we well provided through subjected will available Veris for clearance tool closely a connected The submission The Bluetooth which by global Microsoft year. In as branded security. we there be
third this experience takes step working device implantable product, and i.e. whether monitor it port. full FDA be the the we've de device with will process will to product Design design path, the integration accelerate Mercury the XXXK and a various finalize had The or We're dizziness with a its step pathway. a regulatory the the modular, the development novo version development further we've dubbed with of device. Veris work once on within
two sciences for and time provide amount its data, analytics data substantial will substrate team the out is filled data, engineering. Veris the machine full all with a rich of and system generating and data Veris clinical two Finally, has about a which will be data monetizable science physiologic learning data using AI.
advanced along efforts to we've dubbed is Let's Key leaders carpal CarpX limited Product to us imaging cleared into user surgical XXXK invasive using partners cut opinion of drive minimally treat incorporating to explore the improvements. blown now the procedural led Development on tunnel exploratory experience a a be move intraluminal experience have release structures. to have product focused of generating product possibility Project, anatomic our been and syndrome. ligament Initial provide critical on device ultrasound. time to real This to with which full to commercial and the in ultrasound CarpX device CarpX
including to and believe a product, In is attractiveness of proceed case device freeze, per opportunity. design and well cost handheld next and to and of we design ongoing, goods the submission is margin of the, expect and development gross The the work testing features addition clinical including incorporates electronics will integrated console, much the imaging, the the enhance through device testing, decreasing FDA year. development, cadaver ongoing clearance and we commercial additional to design the ultrasound that
these current generation expand Given product. CarpX decided commercialization next not first the we've ultrasound timelines to the for generation device, of projected
have perform of to until the ready results. promising head-to-head without the is treat and endoscope to device we'll cancer version The is by is million a and direct animal market-leading port plenty KOLs esophageal Accept well well. for $X.XX and now designed is product compete with progressing of Barrick ultrasound Medtronic for form device studies our need for inventory through EsoCure, of grow to offering our device EsoCure the advantages the experience work procedures and is continue of development modulation have the launch. to CarpX endoscopically designed is continue our also progressing esophagus and show the console. and chronic the commercial pre Development work and the We
PortIO performed believe to for South EsoGuard human Quick Nathan approved - seven Device, flushing in has Access the We expect design development PortIO's does it is EsoCure first first proceed is established. licensed pipeline does clearance successful device next The future plasma consists not which projects submission the [indiscernible]. not the three vascular yet Vascular with year. is and study development new as and progressing FDA of and whose is and America Implantable fully reminder device implantation device. we Colombia, Intraosseous remainder testing, patients. that is the access three through when Lucid of synergistic sites the highly freeze, research with well path the of our in platform commercial from commercialization not long-term which recently in site require
completed successful of implantation and after infusion them seven of days excellent All patients. have
XX the the device Recruitment procedures product. out now initial allows regulatory days move the IBM next have issues. currently and market with implanted had in success that pathway we decide patients of the with September. group patients complications that patients to in period proceed of no a follow implants the XX-day reassess to are us We up set we'll seven and with established expected XX-day underway in on U.S. pursue patients underwent these is for close These protocol the days. in implantation our Once other some the to well of Europe with or whether or
a technology. platform is infusion NextFlo
this seeks for performed and million day. is by intravenous pumps infusion NextFlo set, The for expensive incorporating it first care product complex, which eliminating revolutionize in one need each the error electronic prone of our the most country to infusions
project. When on team is and and despite validation and with flow research of regulation development relegating regard NextFlo do we with FDA work, research to we features need submission. solve NextFlo testing to solution. to a need of difficulty The not This flow to repeatability to but committed crack encountered good design their the the code to to we issue patient verge progressing We're repeatability. regulation. design have the but required redesign kind - - trying this
over earlier, part we've of as that make company-wide aggressive Finally, mentioned viciously. capital and a initiative approach pipeline to allocating the past couple very the are sure of rationalization months, I to taken we pruning
analysis, the -- for of have development As future foreseeable rather shelved this them a projects or DisappEAR, terminated result certain we've we NextVent. FlexMO and terminated either including Solys,
development will we raised of pursuing the the some we regard types Although in investing consider promising pipeline, have have again, we the bar continue business to projects with and pursue there. and opportunities resources attractive prospects to
before is claims demonstrate and secure optimize This to our prosecution, and submission touched the growth precommercial course including launch provide history, hand generating Lucid the Before commercial products and year. our the regulatory year, reimbursement, Number to steady my claim clearance launch team -- from financials the testing private Thank to utility [indiscernible] me utility and reins one, Veris With connected I'll questions. Number activities. two including proceeding to to advance quickly the our summarize Medicare this volume is data. And this clinical and Esecure reins expansion I've over critical you. advance Dennis centers the priorities number Lucid includes to platform that year. early down of on to Veris an over handing generate driving a three Dennis, initiatives dot laboratory the of with the company-wide strategic next update development through our with test operations and to that, clearly devices commercial let remarks. is completing clinical sales
